B. Ariceta

发表

Strategy for identification of a potential inherited leukemia predisposition in a 299 patient's cohort with tumor-only sequencing data.

F. Prósper, M. Calasanz, I. Vázquez, 2020, Leukemia research.

The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients

M. Tormo, F. Prósper, M. Calasanz, 2022, Frontiers in Oncology.

Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

F. Prósper, M. Calasanz, M. Sanz, 2022, Blood advances.

Assessment of Minimal Residual Disease by Next Generation Sequencing in Peripheral Blood as a Complementary Tool for Personalized Transplant Monitoring in Myeloid Neoplasms

F. Prósper, M. Calasanz, E. Bandrés, 2020, Journal of clinical medicine.

Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design

F. Prósper, M. Calasanz, I. Vázquez, 2020, PloS one.

Biallelic TET2 mutation sensitizes to 5-azacitidine in acute myeloid leukemia

Lani F. Wu, S. Altschuler, F. Prósper, 2021, medRxiv.

Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia

Lani F. Wu, S. Altschuler, T. Haferlach, 2023 .

Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide

T. Ezponda, A. Ullate-Agote, A. Vilas-Zornoza, 2024, Nature communications.

Single cell profiling of del(5q) MDS unveils its transcriptional landscape and the impact of lenalidomide

T. Ezponda, A. Ullate-Agote, A. Vilas-Zornoza, 2023, bioRxiv.